Back to search results

Decitabine in Combination With Standard of Care Therapy for the Treatment of Surgically Resectable HPV-Negative Head and Neck Cancer

Abroad (travel likely)RecruitingPHASE1

Conditions

Human Papillomavirus-Negative Neck Squamous Cell Carcinoma · Resectable Head and Neck Squamous Cell Carcinoma · Resectable Human Papillomavirus-Independent Head and Neck Mucosal Squamous Cell Carcinoma · HPV-Negative Squamous Cell Carcinoma · Resectable Head and Neck Squamous-cell Carcinoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Mayo Clinic in Florida, Jacksonville, Florida, United States

    Contact: Study coordinator (Clinical Trials Referral Office) · mayocliniccancerstudies@mayo.edu · 855-776-0015
    Contact: Principal Investigator (Adam L. Holtzman, MD)
Study leads

  • Adam L. Holtzman, MD

    Principal Investigator

    Mayo Clinic

View source on ClinicalTrials.gov(opens in a new tab)